Brief: Kiniksa Pharmaceuticals Provides Corporate Update

Kiniksa Pharmaceuticals International

04/01/2024 12:43

Jan 4 (Reuters) - Kiniksa Pharmaceuticals Ltd  KNSA.O :
    * KINIKSA PHARMACEUTICALS PROVIDES CORPORATE UPDATE
    * CASH RESERVES OF $206.3 MILLION (UNAUDITED) EXPECTED TO
FUND
OPERATIONS INTO AT LEAST 2027
    * - ABIPRUBART PHASE 2 RHEUMATOID ARTHRITIS DATA FROM COHORT
4
EXPECTED IN Q2 2024
    * ARCALYST 2024 NET PRODUCT REVENUE EXPECTED TO BE $360 -
$380
MILLION

Source text for Eikon:  ID:nGNX6wXzqW 
Further company coverage:  KNSA.O 

 ((Reuters.Briefs@thomsonreuters.com;))